Share Buyback Plan Approved by Zymeworks (NASDAQ:ZYME)

Zymeworks (NASDAQ:ZYME) announced that its board has approved a stock repurchase plan on Thursday, May 14th, RTT News reports. The company plans to buyback $125.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 7% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Truist Financial raised Zymeworks to a “strong-buy” rating in a research report on Monday, April 27th. HC Wainwright raised their target price on Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Stifel Nicolaus raised their target price on Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research report on Monday, April 20th. Finally, Wells Fargo & Company raised their target price on Zymeworks from $33.00 to $34.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zymeworks presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Zymeworks Stock Down 2.5%

NASDAQ:ZYME traded down $0.61 on Thursday, hitting $23.96. The stock had a trading volume of 557,477 shares, compared to its average volume of 621,590. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -17.49 and a beta of 1.20. The business’s 50-day simple moving average is $25.65 and its two-hundred day simple moving average is $24.28. Zymeworks has a 52-week low of $10.93 and a 52-week high of $29.75.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The firm had revenue of $2.41 million during the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%. As a group, equities research analysts anticipate that Zymeworks will post 1.64 EPS for the current year.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Zymeworks authorized a new 2026 share repurchase program for up to $125 million, a move that can boost shareholder value and support the stock. Article Title
• Positive Sentiment: The company affirmed liquidity while ending the prior repurchase program after buying back a meaningful amount of stock, reinforcing balance-sheet confidence. Article Title
• Neutral Sentiment: HC Wainwright updated its earnings estimates for Zymeworks, raising FY2026 and Q3 2026 forecasts while trimming Q2 2026 and Q4 2026 estimates; the firm kept a Buy rating and $46 price target.
• Neutral Sentiment: Zymeworks also announced upcoming investor conference appearances, which should help keep the company visible to investors but is not, by itself, a major catalyst. Article Title
• Negative Sentiment: The latest earnings-related coverage noted a mix of progress and pressure, underscoring that the company is still navigating uneven near-term fundamentals despite its longer-term pipeline story. Article Title

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.